US2021113612A1PendingUtilityA1

Blood Plasma and Plasma Fractions as Therapy for Tumor Growth and Progression

63
Assignee: ALKAHEST INCPriority: Apr 28, 2016Filed: Dec 23, 2020Published: Apr 22, 2021
Est. expiryApr 28, 2036(~9.8 yrs left)· nominal 20-yr term from priority
A61K 35/16A61P 35/00
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to treating individuals with cancer by using blood plasma or blood plasma fractions as treatment.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A method of treating a cancer, the method comprising administering an effective amount of a blood plasma product to a subject diagnosed with the cancer. 
     
     
         2 . The method of  claim 1 , wherein the blood plasma product is a young plasma. 
     
     
         3 . The method of  claim 1 , wherein the blood plasma product is a Plasma Fraction. 
     
     
         4 . The method of  claim 3 , wherein the Plasma Fraction is a Plasma Protein Fraction. 
     
     
         5 . The method of  claim 4 , wherein the Plasma Protein Fraction is a commercially available Plasma Protein Fraction. 
     
     
         6 . The method of  claim 3 , wherein the Plasma Fraction is a protein-enriched plasma protein product. 
     
     
         7 . The method of  claim 1 , wherein the cancer is comprised of a solid tumor. 
     
     
         8 . The method of  claim 1 , wherein the cancer is a hematopoietic cancer. 
     
     
         9 . The method of  claim 1 , wherein the cancer is a colorectal cancer. 
     
     
         10 . The method of  claim 1 , wherein the cancer is a gastric cancer. 
     
     
         11 . The method of  claim 1 , wherein the cancer is a liver cancer. 
     
     
         12 . The method of  claim 1 , wherein the cancer is a B lymphocyte Burkitt's lymphoma. 
     
     
         13 . The method of  claim 1 , wherein the cancer is a renal cancer. 
     
     
         14 . The method of  claim 1 , wherein the cancer is a thymic cancer.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.